Lacabaratz-Porret Christine, Viard Jean-Paul, Goujard Cécile, Lévy Yves, Rodallec Audrey, Deveau Christiane, Venet Alain, Sinet Martine
INSERM E0109, Le Kremlin Bicêtre, France.
J Acquir Immune Defic Syndr. 2004 May 1;36(1):594-9. doi: 10.1097/00126334-200405010-00007.
HIV-specific CD4+ T-helper cell responses in 40 subjects with chronic infection (CI) who had virus suppression after highly active antiretroviral therapy (HAART) were compared with those in 34 subjects treated during primary infection (PI). A CD4+ T-cell proliferative response to HIV p24 protein was present in 50% of these subjects compared with 79% of subjects treated during PI. The existence of a proliferative response in CI subjects was associated with a higher CD4+ T-cell count at initiation of HAART, a longer duration of virus suppression, and a higher CD4+ T-cell count at the time of analysis. These results show that an HIV-specific proliferative response is preferentially observed in treated CI subjects with CD4+ T-cell counts of >200/microL. However, in treated CI subjects with a significant degree of CD4+ T-cell depletion (<200/microL), it may also be observed in 35% provided that the duration of virus suppression is long enough, which may have implications for future therapeutic strategies.
将40名接受高效抗逆转录病毒疗法（HAART）后病毒得到抑制的慢性感染（CI）受试者的HIV特异性CD4 +辅助性T细胞反应，与34名在原发性感染（PI）期间接受治疗的受试者的反应进行了比较。这些受试者中，50%对HIV p24蛋白有CD4 + T细胞增殖反应，而在PI期间接受治疗的受试者中这一比例为79%。CI受试者中存在增殖反应与HAART开始时较高的CD4 + T细胞计数、较长的病毒抑制持续时间以及分析时较高的CD4 + T细胞计数相关。这些结果表明，在CD4 + T细胞计数>200/μL的接受治疗的CI受试者中，优先观察到HIV特异性增殖反应。然而，在CD4 + T细胞显著耗竭（<200/μL）的接受治疗的CI受试者中，如果病毒抑制持续时间足够长，35%的受试者也可能观察到这种反应，这可能对未来的治疗策略有影响。
